PhaseBio Pharmaceuticals, Inc. (PHAS)
SG&A Expense Growth
-99.88%
Fiscal year · Period ending:
PHAS SG&A Expense Growth
Latest reported-99.88%period ending
Latest reported-99.88%period ending
PHAS FY SG&A Growth (YoY) (0.00% → -99.88%)
Latest values, visible window
High-resolution chart · PNG
PHAS sg&a expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expense Growth |
|---|---|
| -99.8771% | |
| 17.0034% | |
| 130.3068% | |
| 108.634% | |
| 9.5529% | |
| 0% |